In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of the disease.
Join us as Dr. Jennifer Domm of the Sarah Cannon Research Institute at TriStar Centennial sharesÌýthe story of how CRISPR-Cas9 gene editingÌýwasÌýdeveloped and describes how the technology has helped her treat an intractable, inherited, and painful blood disorder that affects some 100,000 Americans.ÌýEven after this treatment gained FDA approval for cell-based gene therapies for the treatment of sickle cell disease in 2023, there remain many barriers to commercial access. However, when it delivers a patient from the traumas of pain and frequent hospitalizations to a “normalâ€� life it seems nothing short of miraculous. Register now for free to discover the promise of CRISPR Cas 9 that extends beyond medical treatment. It can also be used to study genetic functions or to develop pest and disease resistant agricultural products.
This ACS Webinar is moderated by Dr. Cheng Fang of Annovis Bio and isÌýco-produced with the Science History Institute as part of the Joseph Priestley Öйú365betÖÐÎĹÙÍø (JPS) series that promotes a deeper understanding of science, technology, and industry, with an emphasis on innovation and entrepreneurship.
* If you are having technical difficulties viewing the video please try different internet browsers like Chrome, Firefox, and Explorer. If you still can not access the video please review the followingÌýÌýfrom our video hosting platform.
Presenter Slide Deck
Follow along, take notes, and review important details with thisÌýPDF handout of the slides.
"LabNotes" Webinar Summary
Read a 2-page summary distilling this webinar's core concepts and glossary of important terms.
Ìý
What You Will Learn
- The history of how CRISPR became applicable to medicine
- The application of CRISPR-Cas9 to a debilitating and painful morbid disease, sickle cell anemia
- The science and data behind this therapy in patient trials
Co-produced With
Ìý
What an attendee said about this ACS Webinar!
This was one of the most lucid and well-structured presentations I heard recently. The presenter projected her voice correctly and articulated the words clearly, which is frequently missing from presentations lately. The entire talk was very enjoyable and informative. The application of CRISPR technology to diseases originating from point mutations is a great innovaction in medicine. Very timely topic.
BECAUSE PEOPLE
LIKE YOUÌýCREATE
GREAT CHEMISTRY
You Belong Here
;void(0);){kind=link}